Patient Priorities in Treatment Decision‐Making for RRP : A Discrete Choice Experiment
The Laryngoscope · 08.11.2026
DOI: 10.1002/lary.70982 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 08.11.2026. Verfasst von Camryn R Marshall und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, UCSF School of Medicine, San Francisco, California, USA. Die Arbeit nennt 21 Literaturangaben. Gefördert von: UCSF, UCSF Voice & Swallowing Center and the Lewis Francis Morrison, MD Endowed Chair in Laryngology, Sawtooth Software: Academic grant.
Abstract (Originalsprache)
Objective
Recurrent respiratory papillomatosis (RRP) profoundly affects quality of life due to frequent surgeries. Although emerging non‐surgical options such as bevacizumab and HPV‐specific immunotherapies show promise, little is known about patient interest or treatment decision‐making. This study explored RRP patients' treatment preferences using a stated‐preference framework to guide patient‐centered therapy development.
Methods
A two‐part approach was used. First, semi‐structured interviews ( n = 10) with randomly selected RRP patients identified key treatment priorities. The three most frequently cited attributes were incorporated into a discrete‐choice experiment (DCE) distributed to RRP patients with standardized educational materials on bevacizumab and HPV‐specific immunotherapies. Participants completed choice tasks and indicated their preferred treatment. Preferences and attribute importance were estimated using hierarchical Bayes modeling.
Results
Interview participants most often prioritized likelihood of needing future surgery, frequency of non‐surgical treatment, and side effects. Sixty‐six quality‐controlled DCE responses were analyzed. All attributes significantly influenced treatment choice ( p < 0.001) and followed logical, monotonic utility patterns. Side effects were most influential (55.1%), followed by likelihood of future surgery (36.5%) and treatment frequency (8.4%). Overall, patients preferred HPV‐specific immunotherapy (48%) or bevacizumab (44%) over awake or asleep surgery (8%).
Conclusion
This is the first quantitative study of RRP patient treatment priorities. We found that patients overwhelmingly value therapies that reduce surgical burden and side effects, highlighting a critical unmet need in current management. These findings capture the patient perspective and establish a foundation for aligning future research and clinical efforts with what matters most to those living with RRP. Level of Evidence N/A.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, UCSF School of Medicine, San Francisco, California, USA.
- Mass Eye and Ear, Boston, Massachusetts, USA.
ORCID-Profile: Clark A Rosen, Matthew R Naunheim
Förderung
- UCSF
- UCSF Voice & Swallowing Center and the Lewis Francis Morrison, MD Endowed Chair in Laryngology
- Sawtooth Software: Academic grant
- University of California, San Francisco
Zitieren
APA
Marshall, C. R., Jackson, R. W., Watters, B., Rosen, C. A., & Naunheim, M. R. (2026). Patient Priorities in Treatment Decision‐Making for RRP : A Discrete Choice Experiment. The Laryngoscope. https://doi.org/10.1002/lary.70982
Vancouver
Marshall CR, Jackson RW, Watters B, Rosen CA, Naunheim MR. Patient Priorities in Treatment Decision‐Making for RRP : A Discrete Choice Experiment. The Laryngoscope. 2026. doi:10.1002/lary.70982
BibTeX
@article{Marshall2026,
author = {Marshall, Camryn R and Jackson, Riley W and Watters, Brent and Rosen, Clark A and Naunheim, Matthew R},
title = {Patient Priorities in Treatment Decision‐Making for RRP : A Discrete Choice Experiment},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70982}
}
EUVIMED